Alzamend Neuro Files 8-K
Ticker: ALZN · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
Alzamend Neuro filed an 8-K on Nov 18, 2025. Standard update.
AI Summary
Alzamend Neuro, Inc. filed an 8-K on November 18, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and is headquartered in Atlanta, GA.
Why It Matters
This filing indicates Alzamend Neuro, Inc. is providing updates on its corporate activities and financial status to the SEC.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically reports on significant corporate events or financial updates.
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- November 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Atlanta, GA (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' are being reported, but the specific details of these events are not provided in the header information.
What is the Standard Industrial Classification (SIC) code for Alzamend Neuro, Inc.?
The SIC code for Alzamend Neuro, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When is Alzamend Neuro, Inc.'s fiscal year end?
Alzamend Neuro, Inc.'s fiscal year ends on April 30 (0430).
What is the exact business address of Alzamend Neuro, Inc.?
The business address is 480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
What is the registrant's telephone number?
The registrant's telephone number is (844) 722-6333.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 9 · Accepted 2025-11-18 16:30:26
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
Filing Documents
- x11172508k.htm (8-K) — 24KB
- 0001214659-25-016885.txt ( ) — 187KB
- alzn-20251118.xsd (EX-101.SCH) — 3KB
- alzn-20251118_lab.xml (EX-101.LAB) — 33KB
- alzn-20251118_pre.xml (EX-101.PRE) — 22KB
- x11172508k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. Alzamend Neuro , Inc., a Delaware corporation (the " Company ") has learned that Andrew H. Woo, M.D., Ph.D., a director of the Company, passed away on November 14, 2025. Mr. Woo served as a member of the Company's Board of Directors (the " Board ") since its initial public offering in June 2021. William B. Horne, the Chairman of the Board, said, "It is with great sadness that we announce the passing of Andrew H. Woo, M.D., Ph.D. Andy was an outstanding director that provided exceptional inspiration to all of us. He will be deeply missed not just as a respected colleague, but also as a friend. We extend our deepest condolences to his family, friends and those whose life he touched."
01 Financial Statements And Exhibits
Item 9.01 Financial Statements And Exhibits (d) Exhibits: Exhibit No. Description 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: November 18, 2025 /s/ Henry Nisser Henry Nisser Executive Vice President and General Counsel 3